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In establishing a theory to predict male-pattern bald-
ness, we investigated the correlation of testosterone,
epitestosterone, and dihydrotestosterone with 5a-
reductase in hair using gas chromatography-mass
spectrometry. One hundred milligram hair samples
were obtained from a group of balding subjects and
their sons, as well as from a corresponding aged-
matched, nonbalding group. The ratio of testoster-
one to epitestosterone was signi®cantly greater
(mean 46.41, p < 0.001; mean 35.83, p< 0.001,
respectively) in the hair of balding fathers (n = 19,
age 28±50 y) and their sons (n= 16, age 8±16 y) than
in the hair of the nonbalding control subjects (mean
9.17 and 10.47, respectively). These ®ndings demon-
strate that analysis of terminal hair may not only
provide a basis for predicting baldness when the sub-
ject is still young, but also for preventing and treat-
ing male-pattern baldness by controlling the steroid
hormone balance. Key words: dihydrotestosterone/GC-
MS/hair/steroids. J Invest Dermatol 116:57±61, 2001
B
alding is generally associated with aging, and the
desire to prolong a youthful appearance inevitably
leads to demands for effective treatment. Changing
attitudes in modern society have resulted in indivi-
duals' becoming concerned about their appearance
and less tolerant about conditions that might be alleviated by
medical intervention. Recently, certain products under investiga-
tion have stimulated new interest in preventing baldness. These
products have shown the ability to retard or reverse male-pattern
baldness (MPB) in certain individuals (McClellan and Markham,
1999; Scow et al, 1999). MPB is the most common type of hair loss,
representing close to 95% of hair loss cases. It is generally accepted
that MPB is a direct consequence of both androgenic stimulation
and genetic predisposition (Hamilton, 1942).
In 1986, Villez and Dunn reported that women showing a
marked increase in the 3a,17b-androstanediol glucuronide to sex
hormone binding globulin ratio and low serum sex hormone
binding globulin value were noted to have female-pattern baldness.
Recently, Ellis et al (1998, 1999) analyzed the 5a-reductase genes
of balding and nonbalding subjects, and the role of insulin in the
regulation of androgen metabolism and the hair growth cycle in
MPB. They reported that the genes encoding the two iso-enzymes
of 5a-reductase and insulin are not associated with MPB. No
concrete pattern of inheritance in MPB has been observed to date.
MPB has been revealed to be dependent on the interplay
between androgen receptors, the converting enzyme 5a-reductase,
and dihydrotestosterone (DHT), which all concentrate around hair
follicles. Androgen activity is sparked by testosterone when it reacts
with 5a-reductase and converts to DHT. Finasteride, one of the
most popular drugs used in the medical treatment of MPB, works
by lowering levels of DHT in the body by blocking the enzyme
5a-reductase. 5a-Reductase has no binding af®nity to androgen
receptor sites, and it possesses no androgenic, antiandrogenic, or
other steroid-hormone-related properties (Sudduth and
Koronkowski, 1993). It is associated with the nuclear membrane
and cytosol portions of cells, and is found in high concentrations in
the male reproductive tissues, skin, and liver. Furthermore, several
studies have shown increased 5a-reductase activity in the bald-scalp
regions (Bingham and Shaw, 1973; Schweikert and Wilson, 1974;
Puerto and Mallol, 1990).
The role of 5a-reductase inhibitors is not yet fully understood.
Based on the pathophysiology of male pseudohermaphroditism, it
seems that hirsutism, baldness, and acne may respond to treatment
with 5a-reductase inhibitors, which show promise in the treatment
of a number of androgen-dependent disorders (Harris and
Kozarich, 1997). Several observations indicate that the antiandro-
genic epitestosterone, a naturally occurring steroid in the human
body and the 17a-epimer of testosterone, may suppress the
conversion of androgen testosterone to DHT by inhibiting 5a-
reductase activity (Nuck and Lucky, 1987; Starka et al, 1989;
Starka, 1993). Although there are a number of reports detailing the
amounts of androgen receptors and/or 5a-reductase in hair follicle
tissues in androgenetic alopecia (Sawaya and Price, 1997; Hibberts
et al, 1998), the etiology of MPB is not clear, and no correlation has
yet been found between baldness and androgen plasma levels
(Phillipou and Kirk, 1981; Caballero et al, 1990). Further
knowledge of the androgen levels and metabolism at pilosebaceous
level may therefore help us to understand the process.
In 1999, by using gas chromatography-mass spectrometry (GC-
MS), we determined the steroids related to androgen biosynthesis
and estrogens, such as estrone and 17b-estradiol in hair (Choi and
Chung, 1999; Choi et al, 2000). Based on these ®ndings we
compared the levels of DHT, epitestosterone, and testosterone in
the hair of 19 balding fathers (aged 28±55) and 16 of their sons
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(aged 8±16) and in the hair of a control group comprising 55 age-
matched and sex-matched nonbalding subjects.
MATERIALS AND METHODS
Chemicals Testosterone (4-androsten-17b-ol-3-one), epitestosterone
(4-androsten-17a-ol-3-one), and DHT (5a-androstan-17b-ol-3-one)
were purchased from Sigma (St Louis, MO). A 6:1 (vol/vol) mixture of
d3-testosterone and d3-epitestosterone, an internal standard (IS), which was
obtained from Cologne Laboratory (Institute of Biochemistry, German
Sports University, Germany), was dissolved in methanol to give
concentrations of approximately 3 ng per ml and 0.5 ng per ml,
respectively, for accuracy in the testosterone/epitestosterone (T/E; Choi
et al, 1999). To compensate for instrumental variations and losses during
sample preparation, it was necessary to correct them by isotope-labeled IS.
Penta¯uorophenyldimethylsilyl chloride (¯ophemesyl chloride), N-
methyl-N-trimethylsilyltri¯uoroacetamide (MSTFA), ammonium iodide
(NH4I), and dithioerythritol (DTE) were purchased from Sigma.
Preparation of standard solution A stock solution of the three steroids
was prepared at concentrations of 0.1 mg per ml in methanol. The stock
solution was used to prepare a working solution of varying concentrations
(0.01±1.0 mg per ml) in methanol.
Sample preparation and pretreatment Human hair samples were
obtained simply by cutting the tip portions of each subject's scalp hair.
Whenever possible the hair samples were collected from all sites of the
scalp, such as frontal, occipital, temporal, and nuchal. The subjects
constituted two groups: 35 balding fathers (aged 28±55) and their sons
(aged 8±16) in the balding group, and 55 nonbalding age-matched subjects
in the nonbalding group. To prevent contamination with steroids from
sweat, sebum, etc., the hair was washed ®rst with ethanol, water, and then
acetone. After they had been dried (60°C), the hair ®bers were cut into
short lengths of about 1±2 mm, and amounts of 100 mg were weighed into
glass test tubes. The pretreatment was modi®ed alkaline digestion; liquid-
liquid extraction is well established for testosterone detection in the hair
and urine (Choi and Chung, 1999; Choi et al, 1999). Ten microliters of an
IS solution and 1 ml of 1 M NaOH were added, and the solution was
heated at 80°C for 1 h. Then, 1 ml of 0.1 M phosphate buffer (pH 7.0) was
added, and the pH was adjusted to 10±11 by adding 0.3 ml of 2 M HCl,
together with 5 ml of n-pentane. The mixture was mechanically shaken
(10 min) and centrifuged (2400 rpm, 5 min), and the organic phase was
transferred to a test tube. The organic layer was evaporated to dryness with
a rotary evaporator. The residue was dried in a vacuum desiccator over
P2O5/KOH for at least 30 min before the derivatization procedure.
Quality control samples were obtained from the 12 bald cases and the 12
control group individuals. These samples were analyzed in duplicate for
three steroids studied in a day, and they were measured 13 d over a 3 mo
period without particular care for the reproducibility of the present method
in the same manner as described for hair.
Derivatization Flophemesyl chloride (50 ml) was added to the residue,
and the mixture was allowed to stand at room temperature for 15 min.
After excess reagent had been evaporated under a stream of nitrogen at
70°C, trimethylsilylating reagent (40 ml, MSTFA/NH4I/DTE, 1000:4:2,
vol/wt/wt) was added to the residue, and the mixture was heated at 60°C
for 15 min. Approximately 2 ml of the ¯ophemesyl-trimethylsilylating
derivatized sample solution was injected into the gas chromatograph-mass
spectrometer.
The calibration standards were obtained by spiking suitable amounts of
each of these standards into 1 ml of water. Mixtures containing absolute
amounts of several concentrations of each steroid were pretreated,
derivatized, and analyzed in triplicate. To prepare a standard curve, the
ratio of the peak area of steroids to that of d3-epitestosterone as IS was
plotted against the concentration of the steroids in the calibration standard,
and a least-squares linear regression analysis was performed. Values of
unknown concentrations in hair were determined from the regression line
of this calibration curve.
GC-MS The GC-MS system (model 5973MSD combined with a model
6890 plus gas chromatograph, Hewlett-Packard, Avondale, PA) was used in
both scan and SIM modes. The electron energy was 70 eV, and the ion
source temperature was 230°C. The gas chromatograph was equipped with
a 17 m 3 0.2 mm internal diameter 3 0.11 mm ®lm thickness capillary
column coated with a cross-linked methyl silicone gum phase (Hewlett-
Packard). The carrier gas was helium at a column head pressure of 121 kPa.
The splitless method of injection was used. The temperature program was
as follows: initial temperature 220°C (2 min); program rate 4°C per min to
240°C (5 min); 15°C per min up to a ®nal temperature of 310°C, where it
was held for 3.33 min. In the SIM mode for quanti®cation, a molecular ion
peak for each steroid was selected as quantitation ion (m/z 584, 586, and
587). A dwell time of 120 ms and a relative electron multiplier voltage
400 V higher than that in the scanning mode were chosen for each ion
monitored.
Data analysis A least-squares regression analysis was performed on the
measured peak area ratios against the increasing weight ratios of steroids to
IS in order to obtain linearity of SIM responses and to plot calibration
curves for the quantitative measurement of steroids. Using the Microsoft
Excel program, statistical analysis for the level of signi®cance was conducted
by the t test for two independent means or, when appropriate, by the paired
t test. The Pearson correlation coef®cient was used to analyze the univariate
relationship between DHT, epitestosterone, testosterone, and T/E ratio.
RESULTS
Concentrations of DHT, testosterone, and epitestosterone
in hair The studied steroids, DHT, testosterone, and
epitestosterone, were found in different amounts in the balding
and nonbalding groups (Fig 1). The hair of balding fathers
contained signi®cantly higher levels of DHT (mean, 1.19 ng per
g; range, 0.46±2.15 ng per g, p < 0.001) than that of the control
group (0.57 ng per g, 0.38±1.03 ng per g). The sons, varying in ages
before and after puberty at 13, showed amounts of DHT of 0.02±
0.14 ng per g (mean, 0.05 ng per g) in the balding group, whereas
none was detected in the control group except for two sons who
showed concentrations of 0.03 and 0.04 ng per g (Fig 1a). These
results correspond with Schweikert and Wilson's report (1974), in
which the rate of 5a-reductase activity in the isolated hair of
balding men was increased.
The levels of epitestosterone were shown to be slightly different
between the balding group (mean 0.34 ng per g, p = 0.002, and
0.44 ng per g, p < 0.001, fathers and their sons, respectively) and the
nonbalding group (mean 0.41 ng per g and 0.67 ng per g,
respectively) (Fig 1b). As demonstrated here, the epitestosterone
level in the hair of the subjects decreased from the time they were
children to the time they became adults. In general, epitestosterone
in the human body does not originate from testosterone, and its
excretion is independent of the latter (Starka, 1993). The
production rate of epitestosterone is only about 3% that of
testosterone in adults, whereas its urinary excretion is about a third
that of testosterone (Wilson and Lipsett, 1966). This was found not
to be true in epitestosterone plasma levels, which increase from
childhood to puberty and do not change much during adult life
(Lapcik et al, 1995). Such facts indicated the possibility that the T/E
ratios establish another pattern of their own in hair.
Although testosterone plasma levels were not signi®cantly
different between the balding and nonbalding men (Burton et al,
1979), our studies revealed a difference in testosterone levels
between balding cases (mean 9.47 ng per g, p < 0.001, and mean
5.27 ng per g, p = 0.05, fathers and their sons, respectively) and
nonbalding subjects (mean 2.65 ng per g and 5.01 ng per g, fathers
and their sons, respectively) (Fig 1c). The testosterone content in
the balding fathers' hair was about 3.5 times greater than in hair
from age-matched nonbalding subjects, but the testosterone
contents of the sons' samples were not signi®cantly different
between the two groups.
Evaluation of the T/E ratio as an indicator for
MPB Another interesting observation was the remarkable
increase in T/E ratios in the hair of balding fathers and their
sons. These elevated T/E ratios were the results of a signi®cant
decrease in epitestosterone and a slight increase in testosterone
(Fig 1b, c). In comparing the T/E ratio between the balding group
and nonbalding group (Fig 2), we found that the sons of the
balding group showed a ratio three times higher (mean 35.83, range
30.37±42.54, p < 0.001) than that of the control group (10.47,
6.39±15.95). The difference between the fathers of the two groups
was more clear - the T/E ratio of the balding fathers (mean 46.41,
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range 32.99±68.34, p < 0.001) was about ®ve times that of the
nonbalding fathers (9.17, 6.34±11.41).
Reproducibility of the present method A quality control
sample prepared from 100 mg of hair samples of the 24 subjects was
routinely analyzed with every batch of hair. The steroid levels,
measured 13 times over a 3 mo period without particular care, gave
the following mean values (ng per g) for the balding and control
groups: testosterone, 8.06 6 1.23 and 3.72 6 0.99; epitestosterone,
0.36 6 0.15 and 0.69 6 0.24; DHT, 0.88 6 0.31 and 0.39 6 0.10.
DISCUSSION
The methodologies used are not novel but are worth consideration
(Choi and Chung, 1999; Choi et al, 1999). In principle,
quanti®cation by GC-MS using stable-isotope internal standards
is the optimum method of quantitative analysis. The standards
simultaneously monitor recovery and act as the yardstick for
measuring analyzate. To compensate for the various in¯uencing
factors in GC-MS determination of the T/E ratio, a mixture of
deuterated testosterone and deuterated epitestosterone was added to
the sample. The method is a well-accepted technique used in most
doping control laboratories and yields accurate results and
minimizes imprecision (Nolteernsting et al, 1995; Bowers, 1999).
We considered the reproducibility of the method satisfactory for
routine work in medical laboratories. This was determined in the
course of routine use with a quality control sample for more than
3 mo, with no special care taken to ensure high reproducibility.
Clearly, the precision value as the percentage coef®cient of
variation (%CV) of analysis, in the range 3.2%±7.9%, could have
been greatly improved. The method described, however, is
practical as the required bench-top instrumentation is relatively
inexpensive and widely available in medical laboratories.
Epitestosterone is a naturally occurring component of biologic
¯uids in several mammals, including man. For a long time, it has
been considered a biologically inactive steroid and a metabolite
without any hormonal activity and without any marked relation to
the hormonal state of the body (Wilson and Lipsett, 1966). The
biosynthetic pathway, as well as the site of its formation in the
human body, has not been clearly con®rmed until now. Our study
demonstrated that epitestosterone works in the following way. It
lowers the levels of DHT in hair follicles by inhibiting the reaction
of testosterone to enzyme 5a-reductase. This is accomplished by a
complex action consisting of competitive binding of epitestosterone
to the androgen receptor as an antiandrogenetic and antigonado-
tropic active compound (Nuck and Lucky, 1987; Starka et al,
1989). It can be presumed that the inhibition of 5a-reductase by
epitestosterone is accompanied by reduction of the inhibitor
epitestosterone to epidihydrotestosterone, contributing to a
normalization of the hair growth cycle and a reversal of the hair-
loss process (Fig 3). The production of epidihydrotestosterone from
epitestosterone has been con®rmed by Schmidt and Schweikert
(1986), but the concentration of epidihydrotestosterone was too
low in the hair for us to detect signi®cant changes. Although
Hibberts et al (1998) reported some interesting results about the
Figure 1. Levels of DHT, epitestosterone, and testosterone found in the hair samples. (a) DHT; (b) epitestosterone; (c) testosterone. They were
comparatively different in the balding fathers and their children compared with age-matched nonbalding subjects as control groups. BF indicates the balding
fathers; NBF, nonbalding fathers; BC, balding fathers' children; and NBC, nonbalding fathers' children.
Figure 2. Comparative T/E ratios in hair samples between the
groups studied. The T/E ratio was signi®cantly elevated (about three to
®ve times, p < 0.001) in balding cases. BF indicates the balding fathers;
NBF, nonbalding fathers; BC, balding fathers' children; and NBC,
nonbalding fathers' children.
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difference in the levels of androgen receptors in dermal papilla cells
between balding and nonbalding scalp, we were unable to link the
results to our study.
The association of MPB and elevated androgen testosterone in
serum has been reported by Wendy et al (1997). This report gave
little information, however, on predicting baldness. In this study,
Figure 3. Hypothetical actions of epitestosterone (eT) as the inhibitor of 5a-reductase close to the hair follicle cells of the nonbalding scalp.
When steroids enter target cells, they can be reduced to more active steroids, which then bind to the receptor with higher af®nity. For the enzyme 5a-
reductase, the inhibition by epitestosterone is accompanied by reduction of the inhibitor to dihydroepitestosterone. Epitestosterone blocks the formation of
DHT, and in this way appears to interrupt a key factor in the development of inherited MPB. As temporary, excessive DHT production in hair follicles
appears to contribute to the pathogenesis of baldness, prevention of this condition may depend upon blocking this pathway of androgen metabolism with
epitestosterone as antiandrogen. The effects of DHT could be arrested intracellularly in the target organ hair follicles either by blocking the enzyme 5a-
reductase that reduces testosterone to DHT, or by the interception of the highly speci®c androgen receptor that binds with DHT by epidihydrotestosterone
produced from epitestosterone.
Figure 4. Reconstructed ion chromatogram
for the determination of DHT, epitestoster-
one, and testosterone as their 3-trimethylsi-
lyl-17-¯ophemesyl derivatives. Comparison of
the bald case and the control subject hair samples
by selected ion-monitoring separated on an Ultra-
1 (17 m 3 0.2 mm internal diameter 3 0.11 mm
®lm thickness) capillary column. For DHT
(tR = 12.78, a), the selected ion was m/z 586, and
the ions for epitestosterone (tR = 11.60, b) and tes-
tosterone (tR = 13.22, c) were m/z 584 as the mo-
lecular ions of 3-TMS-17-¯ophemesyl ether.
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we have created a mass chromatogram window to screen potential
baldness by GC-MS analysis of the three measured steroids in hair
(Fig 4). This chromatogram shows a fairly complete distinction
between the balding group and nonbalding group. In the hair of
balding cases, an abundant amount of DHT was found; however, a
noticeable increase in the epitestosterone level was found in the
control group. Whereas both groups showed no signi®cant
difference in testosterone in the mass chromatogram, the
quantitative level was slightly increased in the hair of the balding
subjects.
This study suggests that a high DHT level and an increased T/E
ratio are characteristic for MPB, the most common type of hair loss
in young men, and this study enables the prediction of hair loss by
the measurement of steroids in hair. We therefore conclude that
measurements of DHT, as well as the T/E ratio, can be useful in
the prediction of MPB in subjects from a young age.
Here we have presented a methodology for baldness discrimina-
tion based on simultaneous quantitative analysis of the three steroids
in hair. Although we started the study with background knowledge
of the two groups, the results remained clear and consistent within
each group's distinction. The study revealed other interesting
®ndings, but given that two-thirds of Caucasian men are noticeably
bald, more experiments using hair of individuals of diverse races is
still required. Further study also needs to be performed on the
genetic factors of the production and activity of epitestosterone as
an inhibitor of 5a-reductase.
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